Thomas Bonnard obtained his PhD in biomedical engineering at Paris Sorbonne Cité University in 2014. His research focuses on the development of nanotools for vascular diseases treatment and diagnostic. He worked at the Laboratory for Vascular Translational Science (Inserm, U1148) directed by prof Letourneur, developing polymeric microparticles functionalised with fucoidan, a seaweed derived polysaccharide which exhibit strong targeting properties towards the injured vascular wall and thrombosis through affinity for P-Selectin. This system was conjugated to a radiotracer and to iron oxide nanoparticles to produce a SPECT and a T2* MRI molecular imaging tools of abdominal aortic aneurysm. He then joined the Baker IDI Heart & Diabetes Institute in Melbourne and worked on smart drug delivery systems for thrombosis, harnessing the pro thrombotic enzyme thrombin to initiate fibrinolysis. In 2015, he received a European fellowship (WHRI academy – Marie Curie COFUND) to work at the NanoBiotechnology lab headed by prof Hagemeyer at the Australian Centre for Blood Diseases where he acquired extensive skills in protein engineering and nanoparticle synthesis. He specifically focused on the biocompatibility of nanomedicines required for clinical translation and is developing fully protein based biodegradable nanoparticles used as molecular imaging probe for vascular diseases. He recently joined, thanks to fellowship from Caen Normandy University (UCN), the Laboratory of Physiopathology and Imaging of Neurological Disorders (PhIND – Inserm U1237) where he develops nanomedecines for stroke diagnostic and therapy.